Logo image
Back
Incidence and Prevalence of Uveitis and Associated Ocular Complications in the United States TriNetX Database
Journal article   Peer reviewed

Incidence and Prevalence of Uveitis and Associated Ocular Complications in the United States TriNetX Database

NILA Kirupaharan, RAYNA F. Marshall, MATTHEW D. Spangler, KAREN R. Armbrust and MEGHAN K. Berkenstock
American journal of ophthalmology, v 276, pp 30-39
01 Aug 2025
DOI: https://doi.org/10.1016/j.ajo.2025.03.032
PMID: 40157445
Featured in Collection :   UN Sustainable Development Goals @ Drexel

Abstract

•Uveitis incidence is higher than previously reported in the literature.•Rising uveitis incidence, with disruptions noted during the COVID-19 pandemic.•Increased prevalence of low vision and blindness in the uveitis cohort.•Sarcoidosis and spondyloarthropathy are common systemic associations with uveitis.•Prednisone is the most used treatment, followed by methotrexate and adalimumab. To analyze the demographics, immunosuppressant use, associated systemic diseases, ocular comorbidities, and incidence and prevalence of uveitis and associated low vision using the United States TriNetX database from 2013-2023. Retrospective cross-sectional and trend study. Subjects with uveitis in the TriNetX database. Subjects with uveitis were identified with International Classification for Disease codes and then divided into anatomic subtypes based on the diagnosis. Incidence and prevalence data were collected from 2013-2023. Additional data collected included demographics, use of systemic immunosuppressive medications, presence of an associated systemic disease, and associated ocular complications. The primary outcomes were the incidence and prevalence of uveitis (annual and cumulative) with additional analysis by anatomic subtype. Secondary outcomes were the incidence and prevalence of low vision (annual and cumulative). Out of the 109,026,851 subjects in the database, 278,333 (0.26%) had a diagnosis of uveitis. The mean age was 56 years (Standard Deviation = 21, 95% Confidence Interval (CI) 55.9-56.1), and the majority were female (n = 149,186; 53.6%, 95% CI 53.4%-53.8%) and white (n = 150,578; 54.1%, 95% CI 53.9%-54.3%). Anterior uveitis was the most common subtype (n = 209,073, 75.1%). Oral prednisone (n = 62,834; 22.6%, 95% CI 22.5%-22.8%) was the most used immunosuppressant and methotrexate (n = 15,817; 5.7%, 95% CI 5.6%-5.8%) was the most prevalent corticosteroid-sparing immunosuppressive agent. Inflammatory spondyloarthropathies (n = 18,372; 6.6%, 95% CI 6.5%-6.7%) were the most frequently associated systemic disease. The cumulative incidence and prevalence of uveitis from 2013-2023 were 212.5 and 260.8 per 100,000 persons, respectively. This study represents one of the largest uveitis populations analyzed in the United States, revealing a rising incidence of all uveitis subtypes and an increase in low vision among affected patients over the past decade in the database. Prospective studies are needed to identify the factors driving these trends and to develop strategies to prevent vision loss and ocular complications in uveitis patients.

Metrics

1 Record Views
16 citations in Web of Science

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: SDGs in the Output

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Ophthalmology
Logo image